RCP
ORKA

Remedium Capital Partners’s Oruka Therapeutics ORKA Stock Holding History

Remedium Capital Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149M Hold
1,565,661
– – 32.99% 1
2026
Q1 		$76.8M Buy
1,565,661
+13,247
+0.9% +$460K 27.31% 1
2025
Q4 		$47.1M Buy
+1,552,414
New +$43.3M 27.64% 2

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Remedium Capital Partners's ORKA Position: Q2 2026 in Review

Remedium Capital Partners held its Oruka Therapeutics (ORKA) position steady in Q2 2026 at 1,565,661 shares worth $149M. The position accounts for 32.99% of the portfolio, ranked #1.

Remedium Capital Partners first reported a position in ORKA in Q4 2025 and has held it in 3 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Remedium Capital Partners held 1,565,661 shares of Oruka Therapeutics worth $149M as of Q2 2026.
  • Remedium Capital Partners left its Oruka Therapeutics share count unchanged in Q2 2026.
  • Oruka Therapeutics made up 32.99% of Remedium Capital Partners's portfolio in Q2 2026, its #1 holding.
  • Remedium Capital Partners first reported a position in Oruka Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Remedium Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.